This is a prospective, non-randomized, multicenter observational registry study designed to systematically evaluate the long-term efficacy and safety of catheter ablation for treating atrial fibrillation (AF) and ventricular tachycardia (VT) in Chinese patients.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age ≥ 18 years.
✓. Diagnosed with atrial fibrillation (AF), including paroxysmal AF (PAF) and persistent AF (PsAF).
✓. Scheduled to undergo first-time catheter ablation for AF.
✓. Procedure to be performed using a 3D mapping system.
✓. Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments.
Exclusion criteria
✕. Severe congenital heart disease (e.g., Tetralogy of Fallot, corrected transposition of the great arteries).
✕. AF secondary to a clearly reversible cause (e.g., hyperthyroidism, post-operative state, acute alcohol intoxication).
✕. Unstable angina pectoris or acute myocardial infarction (MI) within 30 days prior to enrollment/procedure.
✕. Severe active infection (e.g., septic shock, sepsis).
✕. Contraindications to anticoagulation therapy.
✕. Current participation in another interventional clinical trial that may confound the results of this study.
✕. Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study.
What they're measuring
1
Freedom from any documented atrial arrhythmia in 12 months after the index ablation procedure
Timeframe: From the end of the 3-month blanking period post-ablation to the 12-month follow-up
2
Composite outcomes of ventricular tachycardia recurrence, cardiovascular hospitalization, or death during the 12-month follow-up